Conquer Cancer Foundation of ASCO Awards $5.65 Million to Support Cancer Research
The Kidney Cancer Association announces another Young Investigator Award (YIA) made collaboratively with Conquer Cancer Foundation (ASCO). The Award is a research grant that supports promising investigators and encourages quality research in clinical oncology, providing funding during a physician ’s pivotal career transition from a fellowship program to a faculty appointment.06/06/2017
Conclusion: Medication-related osteonecrosis of the temporal bone is not a well-known entity among otolaryngologists and could therefore be misclassified as another diagnosis. In patients with othorrea and earache following sorafenib treatment, temporal bone osteonecrosis should be suspected.
This case of a renal cell carcinoma in a 30-year-old highlights the need for screening for hereditary kidney cancer syndromes in patients diagnosed with RCC at a young age.Urologic Nursing
This meta-analysis was performed to evaluate the relationship between hypoxia-inducible factor-1 α (HIF1α) 1790G/A gene polymorphism and the susceptibility to renal cell carcinoma (RCC) and prostate cancer (PCa).
ConclusionThe current results demonstrated that PVT1 and EGOT could serve as potential biomarkers of ccRCC with good performance characteristics.
Conclusions Participants who engaged in weight lifting had a significantly lower risk of colon cancer and a trend toward a lower risk of kidney cancer than participants who did not weight lift.
In conclusion, patients affected by ccRCC with high Lamin-B1 expression exhibit poor prognosis. Lamin-B1 may serve as a tissue-based biomarker for new therapeutic agents targeting therapy-induced senescence. PMID: 31402955 [PubMed]
AbstractBackground.Anlotinib is a tyrosine kinase inhibitor inhibiting angiogenesis. This multicenter, randomized phase II trial aimed to investigate the efficacy and safety of anlotinib in comparison with sunitinib as first‐line treatment for patients with metastatic renal cell carcinoma (mRCC).Materials and Methods.Patients with mRCC from 13 clinical centers were randomly assigned in a 2:1 ratio to receive anlotinib (n = 90) or sunitinib (n = 43). Anlotinib was given orally at a dose of 12 mg once daily (2 weeks on/1 week off), and sunitinib was given orally at 50 mg once daily...
lo Alberto Zaniboni The association between antibiotic use and risk of cancer development is unclear, and clinical trials are lacking. We performed a systematic review and meta-analysis of observational studies to assess the association between antibiotic use and risk of cancer. PubMed, the Cochrane Library and EMBASE were searched from inception to 24 February 2019 for studies reporting antibiotic use and subsequent risk of cancer. We included observational studies of adult subjects with previous exposure to antibiotics and available information on incident cancer diagnoses. For each of the eligible studies, data we...